In order to provide the most relevant content to the readers of HealthCare Business News, we're asking you to share a little information about who you are, (it takes two seconds and then you're done).
Register
Curie Therapeutics and NorthStar enter Actinium-225 deal
NorthStar has given Curie Therapeutics priority access to its supply of n.c.a. Ac-225.
NorthStar Medical Radioisotopes is providing priority access to Curie Therapeutics for its no-carrier-added supply of actinium-225 (Ac-225) to develop treatments for solid tumors.
A high-energy alpha-emitting radioisotope, Ac-225 can be combined with targeting ligands to treat these cancers. But limitations in current production technology have chronically limited available supplies for research and commercial uses.
Curie Therapeutics is developing a multimodal radiopharmaceutical platform to produce a novel class of radioligand Actinium and Lutetium conjugates that precisely target a broad range of solid tumors.
NorthStar will produce the n.c.a. Ac-225 with its electron accelerator technology, which is positioning it to become the first commercial-scale producer of Ac-225. “Radiotherapy shows immense promise in treating many forms of cancer, but has been held back by the very limited supply of radioisotopes such as n.c.a. Ac-225. With commercial scale supply, many thousands of patients can be successfully treated every year,” Stephen Merrick, president and chief executive officer of NorthStar Medical Radioisotopes, told HCB News.
As an n.c.a product, NorthStar’s Ac-225 is free of long-lived radioactive contaminants and byproducts that risk imposing regulatory and waste management challenges on providers. Its electron beam accelerator production method increases capacity and scheduling flexibility.
Curie Therapeutics will use n.c.a Ac-225 and Lu-177 to create Alpha (Ac-225) and beta (Lu-177) emitting payloads, which are each useful for treating specific indications, depending on the type of solid tumor, its biology, the line of therapy and standard of care. “Alpha payloads are optimally positioned for tumors with homogenous target expression, targets with limited off-tumor expression, and can also take on hypoxic tumors. Beta payloads are typically preferred with larger tumors or tumors with more heterogeneous target expression,” Simon Read, chief executive officer of Curie Therapeutics Inc., told HCB News.
NorthStar is also constructing a dedicated Actinium-225 production facility and is planning for operations there to begin in late 2023. It will submit a Drug Master File to the FDA in 2024 to provide cGMP grade Ac-225.
